The top five players in the global dyslipidemia drugs market are AstraZeneca plc., Merck & Co., Inc., Pfizer, Inc., Daiichi Sankyo Company, Limited, and Abbott Laboratories. The cumulative share of these players in the global market was valued at 74.4% in 2014. The exclusivity in the rights of blockbuster drugs has been the primary growth driver for these companies. Analysts predict that intensive research and development activities by these players will determine their success rate and the extent of their role in the growth of the overall market in the near future.
The research report states the global dyslipidemia drugs market is expected to decline to US$6.88 bn by 2023 from US$17.85 bn in 2014. Between 2015 and 2023, the global market is expected to witness a declining CAGR of -10.3%.
Europe Experiences Least Decline in the Global Market
Out of the various drug classes, the fibric acid and omega-3 fatty acid derivatives segment will exhibit the least decline, at a CAGR of -1.6% during the forecast period. Rising number of prescriptions for drugs such as Lovaza, Epanova, and Vascespa will help this segment gain slight momentum in the overall competitive landscape in the coming few years. By the end of 2023, the fibric acid and omega-3 fatty acid derivatives segment will reach a valuation of US$1,003.2 mn.
Geographically, the drop in the Europe dyslipidemia market will be comparatively lower at a -9.9% CAGR between 2015 and 2023. The factors mitigating the losses of the dyslipidemia market across Europe will be supportive norms for the pharmaceutical manufacturing sector and higher consumer spending on branded formulations.
Obesity becomes the Undercurrent for Growth of Dyslipidemia Drugs Market
The high incidence of abnormalities related to triglyceride and cholesterol are expected to encourage the global dyslipidemia market. The changing lifestyles along with increasing cases of obesity due to lack of exercise and consumption of unhealthy food items has given the overall market a fresh boost. Referred to as a serious cardiovascular condition, the growing number of diabetics is also likely to fuel this market over a period of time as high lipoprotein abnormalities such as reduced plasma HDL cholesterol and hypertriglyceridemia are common among type 2 diabetics. Treating these abnormalities requires drug therapy such as statins and other combination drug therapies.
Factors such as ongoing research and development pertaining to the enhancement of existing drug therapies along with discovering new ones have provided an incredible leverage to the overall market. A robust pipeline and commercialization of various drugs are expected to create a good scope for sales of dyslipidemia drugs in the near future. The increasing awareness about diseases amongst the overall global population due to promotional activities has also raised hopes for this market to climb back to positive growth. The relentless efforts made by the government and private organizations to raise awareness and educate the masses about dyslipidemia drugs is expected to boost the demand for drugs in the near future.
Patent Expirations to Reduce Profit Margins for Big Players
As the patents of blockbuster drugs are nearing expiration date, they are likely to create a massive dent in the profits earned by the actual manufacturing companies. Currently, the market is governed by a few big brands, who are likely to lose their patents in the near future, which will hamper their profit margins. The introduction of generic drugs is also expected to increase the competition, by increasing the affordability of drugs equivalent to branded formulations.
“To revive the demand for dyslipidemia drugs and to reduce the manufacturing costs, enterprises must increase their footprint in the emerging economies,” suggests the lead author of this research report. Highly populated countries such as India and China are expected to offer huge patients pools and cheap labor, both of which will benefit the overall market, reports the author.
This review is based on Transparency Market Research’s report, titled “Dyslipidemia Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023.”
- Global dyslipidemia drugs market to decline to US$6.88 bn by 2023
- Europe experiences the least decline at -1.6% CAGR as manufacturers receive regulatory support
- Rising prevalence of obesity holds hope to revive usage of dyslipidemia drugs in near future
The global dyslipidemia drugs market is segmented as follows:
- Global Dyslipidemia Drugs Market, by Drug Class
- Bile Acid Resins
- Fibric acid and Omega-3 Fatty acid Derivatives
- Others (Combination Drugs and Cholesterol Absorption Inhibitors)
- Global Dyslipidemia Drugs Market, by Geography
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
Our new press releases https://www.transparencymarketresearch.com/pressrelease/global-dyslipidemia-market.htm
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453